Key Points - Industry/Company: The content pertains to a pharmaceutical company involved in vaccine development and clinical trials. - Core Points and Arguments: - The company has submitted two product listings for approval. - A second-tier product, the "Elderly Bed," has also been submitted for approval. - In the first quarter of the year, the company filed clinical application materials for five vaccine products. - The materials include an upgraded version of 13 tuberculosis and pneumonia products, 20 tuberculosis and pneumonia products, an inactivated influenza vaccine, and a novel double-deoxyribonucleic acid (DNA) vaccine. - Other Important Content: - No additional information is provided beyond the product submissions and clinical trial activities. [1]
艾美疫苗投资者交流会